Latest News and Press Releases - GlobeNewswire
GlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public.
www.globenewswire.comHere’s the latest available snapshot on Revolution Medicines, based on recent public reporting:
-
Company progress and key assets:
- Daraxonrasib (a pan-RAS inhibitor) remains Revolution Medicines’ leading asset, with ongoing Phase III trials for pancreatic cancer and NSCLC as a monotherapy. Positive interim/regulatory signals have supported investor interest in the asset.[2][3][5]
- The company’s other RAS(ON) programs and collaboration activities (including potential combinations) have been highlighted in industry coverage as part of a broader RAS-focused development push.[3][4]
-
Regulatory and development milestones:
- FDA designations (e.g., orphan drug status and priority pathways) have occurred for some RAS(ON) candidates, contributing to a more favorable regulatory outlook for accelerated development timelines in certain indications.[4][2]
- Enrollment in ongoing pivotal trials, such as the RASolute 302 study in metastatic pancreatic cancer, has been a focal point in 2024–2025 updates, with expectations to complete enrollment in that period according to press releases.[5]
-
Market and funding context:
- Public market coverage and analyst commentary around Revolution Medicines has emphasized potential deal activity and investor interest in its RAS(ON) pipeline, with occasional reports of strategic interest from larger pharma, though with variability in timing and certainty.[3][4]
- The company has pursued financing and collaboration arrangements to support its lead programs, including partnerships and potential licensing discussions, as reported in 2025–2026 coverage.[4]
Illustrative example:
- If you’re evaluating near-term catalysts, watch for: (1) top-line data or interim readouts from the RASolute 302 trial (daraxonrasib in metastatic pancreatic cancer), (2) any FDA/regulatory milestones for daraxonrasib or companion assets, and (3) any disclosed strategic partnerships or financing agreements that could impact timelines or valuation.[5][3]
Would you like a concise timeline of milestones by quarter, or a quick chart of key assets and their current trial phases? I can compile that with sources.